Which direct oral anticoagulant (DOAC) is contraindicated in patients with severe hepatic failure (Child‑Pugh class C)?

DOAC Contraindications in Severe Hepatic Failure

All DOACs (dabigatran, apixaban, edoxaban, and rivaroxaban) are contraindicated in Child-Pugh class C cirrhosis, while rivaroxaban is uniquely contraindicated even in Child-Pugh class B cirrhosis. 1

Child-Pugh Class C (Severe Hepatic Failure)

Complete DOAC contraindication applies to all four agents:

• Dabigatran: Do not prescribe in Child-Pugh C 1
• Apixaban: Do not prescribe in Child-Pugh C 1
• Edoxaban: Do not prescribe in Child-Pugh C 1
• Rivaroxaban: Do not prescribe in Child-Pugh C 1

The 2022 EASL guidelines provide a strong recommendation (Level of Evidence 4) against DOAC use in Child-Pugh C patients due to the risk of drug accumulation and unpredictable anticoagulant effects in severe hepatic impairment. 1

Child-Pugh Class B (Moderate Hepatic Impairment)

Rivaroxaban stands alone as contraindicated in Child-Pugh B cirrhosis:

• Rivaroxaban: Do not prescribe in Child-Pugh B 1
  • Pharmacokinetic studies demonstrate a >2-fold increase in drug exposure in Child-Pugh B patients 1, 2
  • The 2024 ACC/AHA/ACCP/HRS guidelines specifically state rivaroxaban is contraindicated in Child-Pugh B due to potentially increased bleeding risk 1

Other DOACs may be used with caution in Child-Pugh B:

• Apixaban: Consider dose reduction in Child-Pugh B 1
• Dabigatran: Consider dose reduction in Child-Pugh B 1
• Edoxaban: Consider dose reduction in Child-Pugh B 1

Clinical Reasoning

The differential contraindication pattern reflects pharmacokinetic differences:

• Rivaroxaban undergoes 65% hepatic metabolism, making it particularly susceptible to accumulation in hepatic impairment 1
• Apixaban (75% hepatic metabolism) shows only 1.09-fold AUC increase in Child-Pugh B 2
• Edoxaban (50% hepatic metabolism) and dabigatran (20% hepatic metabolism) demonstrate minimal pharmacokinetic changes in moderate hepatic impairment 1, 2

Critical Caveats

Renal function must be simultaneously assessed:

• All DOACs are contraindicated when creatinine clearance <15 mL/min regardless of hepatic function 1
• Dabigatran should not be prescribed when CrCl 15-30 mL/min 1
• Combined hepatorenal dysfunction (common in cirrhosis) creates compounded contraindications 1

Coagulopathy assessment is essential:

• DOACs are contraindicated in hepatic disease associated with coagulopathy and clinically relevant bleeding risk, independent of Child-Pugh classification 1, 2
• Presence of esophageal varices, thrombocytopenia, or active bleeding may represent additional contraindications even in Child-Pugh A/B 1